Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
37
JSPR Quote, Financials, Valuation and Earnings
Last price:
$1.84
Seasonality move
:
-19.89%
Day range:
$1.78 - $1.85
52-week range:
$1.39 - $22.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
4.43x
Volume:
209.7K
Avg. volume:
2.8M
1-year change:
-91.57%
Market cap:
$51.2M
Revenue:
--
EPS (TTM):
-$5.90
Analysts' Opinion
-
Consensus RatingJasper Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.86, Jasper Therapeutics, Inc. has an estimated upside of 875.8% from its current price of $1.83.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.00 representing 100% downside risk from its current price of $1.83.
Fair Value
-
According to the consensus of 7 analysts, Jasper Therapeutics, Inc. has 875.8% upside to fair value with a price target of $17.86 per share.
JSPR vs. S&P 500
-
Over the past 5 trading days, Jasper Therapeutics, Inc. has overperformed the S&P 500 by 4.9% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Jasper Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Jasper Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Jasper Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Jasper Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Jasper Therapeutics, Inc. reported earnings per share of -$1.13.
Enterprise value:
2M
EV / Invested capital:
0.15x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-0.03x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1M
Return On Assets:
-133.52%
Net Income Margin (TTM):
--
Return On Equity:
-204.39%
Return On Invested Capital:
-195.32%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$1.4M | -$1.4M | -$1M | -$541K | -$229K | |
| Operating Income | -$64.9M | -$68.7M | -$93.3M | -$19.9M | -$19.2M | |
| EBITDA | -$63.5M | -$67.3M | -$92.3M | -$19.3M | -$18.9M | |
| Diluted EPS | -$8.29 | -$4.75 | -$5.90 | -$1.24 | -$1.13 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $102.4M | $52.4M | $105.2M | $94.8M | $54.6M | |
| Total Assets | $107.2M | $59.1M | $110.4M | $99.4M | $57.5M | |
| Current Liabilities | $9.2M | $7.4M | $11.9M | $12.5M | $21M | |
| Total Liabilities | $28.6M | $10.9M | $16.3M | $13.5M | $43.6M | |
| Total Equity | $78.6M | $47.6M | $94.1M | $83.7M | $11.6M | |
| Total Debt | $3M | $3M | $2.1M | $1M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.2M | -$57.9M | -$76.4M | -$14.1M | -$17M | |
| Cash From Investing | -$119K | -$686K | -$71K | -$274K | -- | |
| Cash From Financing | $101.3M | $47.3M | $34.9M | $9K | $28.4M | |
| Free Cash Flow | -$48.4M | -$58.6M | -$76.5M | -$14.3M | -$17M | |
JSPR
Sector
Market Cap
$51.2M
$28M
Price % of 52-Week High
7.96%
51.03%
Dividend Yield
0%
0%
Shareholder Yield
-52.21%
-1.54%
1-Year Price Total Return
-91.57%
-17.48%
Beta (5-Year)
2.688
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.79
200-day SMA
Sell
Level
$3.48
Bollinger Bands (100)
Sell
Level
1.86 - 2.74
Chaikin Money Flow
Sell
Level
-52.3M
20-day SMA
Buy
Level
$1.77
Relative Strength Index (RSI14)
Buy
Level
50.25
ADX Line
Buy
Level
20.81
Williams %R
Neutral
Level
-36.1111
50-day SMA
Sell
Level
$1.95
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Sell
Level
-4
On Balance Volume
Sell
Level
-49.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (5.5522)
Sell
CA Score
(Annual)
Level (-3.0897)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (8.8743)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
Stock Forecast FAQ
In the current month, JSPR has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The JSPR average analyst price target in the past 3 months is $17.86.
-
Where Will Jasper Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Jasper Therapeutics, Inc. share price will rise to $17.86 per share over the next 12 months.
-
What Do Analysts Say About Jasper Therapeutics, Inc.?
Analysts are divided on their view about Jasper Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Jasper Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $4.00.
-
What Is Jasper Therapeutics, Inc.'s Price Target?
The price target for Jasper Therapeutics, Inc. over the next 1-year time period is forecast to be $17.86 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is JSPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Jasper Therapeutics, Inc. is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of JSPR?
You can purchase shares of Jasper Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Jasper Therapeutics, Inc. shares.
-
What Is The Jasper Therapeutics, Inc. Share Price Today?
Jasper Therapeutics, Inc. was last trading at $1.84 per share. This represents the most recent stock quote for Jasper Therapeutics, Inc.. Yesterday, Jasper Therapeutics, Inc. closed at $1.83 per share.
-
How To Buy Jasper Therapeutics, Inc. Stock Online?
In order to purchase Jasper Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get JSPR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
JSPR
Sector
P/E ratio
--
23.89x
PEG ratio
-0.01x
-0.01x
P/B ratio
4.43x
1.82x
Price / LTM sales
--
1.60x
Growth Metrics
JSPR
Sector
Revenue growth
--
4.62%
Earnings growth
9.35%
10.88%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$1.29
-$0.21
Profitability
JSPR
Sector
Profitability FY 2024
-$1.4M
$3.5M
Return on invested capital
-195.32%
-31.77%
Return on assets
-133.52%
-27.96%
Return on equity
-204.39%
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
9
Balance Sheet
JSPR
Sector
Total cash
$50.9M
$26.3M
Short term investments
--
$25.7M
Total assets
$79.9M
$78M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
